Colorectal cancer is a carcinoma arising from the luminal surface of the colon.
It is the 2nd most common cancer in women and third most common cancer in male worldwide. It commonly arises from adenomatous polyps.
It is strongly linked to age with 83% occurring in people ≥60 years old.
Rectal cancer is defined as cancerous lesions located within 12 cm of the anal verge.
Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.
A triple-drug combination therapy comprising encorafenib, binimetinib, and cetuximab significantly improved survival compared with the current standard of care chemotherapy in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had failed one or two prior treatments, according to the BEACON CRC study presented at the recent ESMO World Congress on Gastrointestinal Cancer (ESMO GI).
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approval. Supplemental approvals may have occurred since the original approval date.
Consuming an average level of 76 g of red and processed meat daily, which meets the current recommendation of ≤90 g/day, nonetheless contributes to an increased risk of colorectal cancer, a UK study has found.
The antiplatelet drug clopidogrel, used alone or in combination with low-dose aspirin, cuts the risk of colorectal cancer by a magnitude comparable to that conferred by low-dose aspirin monotherapy, with the risk reduction apparent at 1 year of treatment, according to a study.
Adding high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer (mCRC) may confer potential benefit to previously untreated patients in terms of progression-free survival (PFS) compared with supplemental standard-dose vitamin D3, suggests the phase II SUNSHINE* study.
The use of molecular screening to guide treatment decisions in advanced cancer is not recommended in routine clinical practice due to the limited benefit observed, according to investigators of the ProfiLER trial.
A watchful waiting approach appears to be an attractive route for sphincter preservation in select rectal cancer patients achieving clinical complete response with neoadjuvant therapy, according to a recent study. However, some may develop local regrowth, which is associated with a higher risk of distant progression and worse survival.
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.